Single Dose Safety Study of SB-656933 in People with CF
Study Type:
Interventional
Intervention Category:
Anti-Inflammatory
Study Sponsor:
GSK
Study Phase:
1
Recruitment Status:
Trial Completed
Study Drug(s):
SB-656933
Number of Participants Being Recruited:
16
Single / Multi-Center:
Multi-Center
STUDY BACKGROUND INFORMATION:
Some medications taken by people with CF are rapidly cleared by body systems. In the laboratory tests this study medication showed less rapid clearing. This study will look at the effect on safety and clearance from the body after taking one dose of SB-656933 in people with CF.
ELIGIBILITY
Age:
>= 16 Years
FEV1:
>= 40 Percent Predicted
P. aeruginosa status:
Not applicable
B. cepacia status:
Negative
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
CA
Stanford University (Adult), Palo Alto, CA, 94305
Contact Information:
Dunn, Colleen Phone: (650) 736-0388 Email: cedunn@stanford.edu
MN
The Minnesota Cystic Fibrosis Center (Adult), Minneapolis, MN, 55455
Contact Information:
Grover, Patricia Phone: (612) 626-7425 Email: Grove026@umn.edu
PA
University of Pittsburgh School of Medicine (Adult), Pittsburgh, PA, 15213
Contact Information:
Hartigan, Elizabeth Phone: (412) 692-7060 Email: elizabeth.hartigan@chp.edu
